Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANGO 
AngioDynamics Inc (ANGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: ANGO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -42.8% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 390.90M USD | Price to earnings Ratio - | 1Y Target Price 15.33 |
Price to earnings Ratio - | 1Y Target Price 15.33 | ||
Volume (30-day avg) 494991 | Beta 0.56 | 52 Weeks Range 5.47 - 13.50 | Updated Date 04/1/2025 |
52 Weeks Range 5.47 - 13.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-04-02 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -78.44% | Operating Margin (TTM) -6.96% |
Management Effectiveness
Return on Assets (TTM) -5.84% | Return on Equity (TTM) -76.44% |
Valuation
Trailing PE - | Forward PE 96.15 | Enterprise Value 330844007 | Price to Sales(TTM) 1.36 |
Enterprise Value 330844007 | Price to Sales(TTM) 1.36 | ||
Enterprise Value to Revenue 1.15 | Enterprise Value to EBITDA -137.63 | Shares Outstanding 40465700 | Shares Floating 36909178 |
Shares Outstanding 40465700 | Shares Floating 36909178 | ||
Percent Insiders 5.62 | Percent Institutions 83.59 |
Analyst Ratings
Rating 4.67 | Target Price 15.33 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
AngioDynamics Inc
Company Overview
History and Background
AngioDynamics, Inc. was founded in 1988. It is a medical device company that designs, develops, manufactures, and markets a wide range of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease.
Core Business Areas
- AngioDynamics Devices: Includes AngioVac, BioFlo PICC, NanoKnife, and other devices used in vascular access, oncology, and surgery.
Leadership and Structure
Jim Clemmer is the Chief Executive Officer. The company has a typical corporate structure with various departments including Sales, Marketing, R&D, and Operations.
Top Products and Market Share
Key Offerings
- AngioVac: A vacuum-assisted veno-venous bypass system used for removing thrombus or other undesirable material from the vasculature. Competitors include Penumbra and Inari Medical. Market share data is not publicly available. Estimated annual revenue is in the tens of millions USD.
- BioFlo PICC: Peripherally inserted central catheter with BioFlo technology designed to resist thrombus accumulation. Competitors include Becton Dickinson and Teleflex. Market share data is not publicly available. Estimated annual revenue is in the tens of millions USD.
- NanoKnife: Irreversible Electroporation (IRE) system used for ablating tumors. Competitors include Medtronic. Market share data is not publicly available. Estimated annual revenue is in the tens of millions USD.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, regulatory scrutiny, and intense competition. Trends include minimally invasive procedures, personalized medicine, and the increasing use of technology.
Positioning
AngioDynamics is positioned as a provider of innovative medical devices focused on minimally invasive therapies in vascular access, oncology, and surgery. It aims to differentiate through technology and clinical outcomes.
Total Addressable Market (TAM)
The TAM for AngioDynamics' product lines is estimated to be in the billions of dollars. AngioDynamics has a small share of this TAM, focusing on niche areas within the broader interventional medicine market.
Upturn SWOT Analysis
Strengths
- Innovative Product Portfolio
- Strong relationships with physicians
- Focused on Minimally Invasive Procedures
Weaknesses
- Smaller size compared to major competitors
- Limited marketing and sales resources
- Dependence on a few key products
Opportunities
- Expanding into new geographic markets
- Developing new applications for existing technologies
- Acquiring complementary technologies or businesses
Threats
- Intense competition from larger companies
- Pricing pressure from healthcare providers
- Regulatory changes affecting medical device approval
Competitors and Market Share
Key Competitors
- BDX
- TFX
- MDT
Competitive Landscape
AngioDynamics competes with larger, more established medical device companies. Its competitive advantage lies in its innovative product portfolio and focus on minimally invasive procedures. It's disadvantaged due to its smaller size and limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: AngioDynamics' growth has been driven by product innovation and market expansion.
Future Projections: Future growth is expected to be driven by new product launches and strategic acquisitions.
Recent Initiatives: Recent initiatives include the development of new product lines and expansion into new markets.
Summary
AngioDynamics is a smaller player in the competitive medical device market, known for its innovative products in minimally invasive therapies. Its strengths lie in its niche product portfolio, but it faces challenges due to its size and competition from larger companies. Strategic acquisitions and successful product launches will be crucial for future growth. They should focus on product improvement and expanding TAM share.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
MDT
Medtronic PLC
MDT
Medtronic PLC
TFX
Teleflex Incorporated
TFX
Teleflex Incorporated
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data may be estimates and not precise figures. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AngioDynamics Inc
Exchange NASDAQ | Headquaters Latham, NY, United States | ||
IPO Launch date 2004-05-27 | CEO, President & Director Mr. James C. Clemmer | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 748 | Website https://www.angiodynamics.com |
Full time employees 748 | Website https://www.angiodynamics.com | ||
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.